Search

Reporter gene assays are widely used for the assessment of transcription factor activation following xenobiotic exposure of cells. A critical issue with such assays is the possibility of interference of test compounds with the test system, for example, by direct inhibition of the reporter enzyme. Here we show that the pyrrolizidine alkaloid heliotrine interferes with reporter signals derived from GAL4-based nuclear receptor transactivation assays by a mechanism independent of luciferase enzyme inhibition. These data highlight the necessity to conduct proper control experiments in order to avoid perturbation of reporter assays by test chemicals. [ABSTRACT FROM AUTHOR]

The ATP-binding cassette transporters Breast Cancer Resistance Protein (Abcg2) and Multidrug Resistance-associated Protein 2 (Abcc2) play an important role for the hepatobiliary elimination of drugs and toxins as well as their metabolites. Previous in vitro transport studies showed that both transporters are involved in the active efflux of phase II metabolites of carcinogenic benzo[ a ]pyrene (BP), however the role of these carriers in hepatobiliary elimination in vivo is still unknown. In the present study, Abcg2 (−/−) and Abcc2 (−/−) knockout mice were used to elucidate the role of Abcg2 and Abcc2 for the hepatobiliary excretion of BP and its metabolites. After intravenous application of [ 3 H]BP the hepatobiliary excretion was significantly reduced in these mice: whereas wild type mice excreted on average 25.4% of the applied dose into the bile over 90 min, Abcg2 (−/−) knockout mice only excreted 10.7% and Abcc2 (−/−) knockout mice 8.6%. As a consequence, [ 3 H]BP concentrations were in general higher in the plasma and in most of the organs of the Abcg2 and Abcc2 knockout mice. Both transporters may have a protective function for BP-induced carcinogenesis in humans, due to its crucial importance for the hepatobiliary elimination of BP via bile. Subjects with reduced ABCG2 or ABCC2 expression might have higher oral bioavailability for BP due to a reduced excretion and so might be more susceptible to BP-induced carcinogenesis. [ABSTRACT FROM AUTHOR]

In general, xenobiotic metabolizing enzymes (XMEs) are expressed in lower levels in the extrahepatic tissues than in the liver, making the former less relevant for the clearance of xenobiotics. Local metabolism, however, may lead to tissue-specific adverse responses, e.g. organ toxicities, allergies or cancer. This review summarizes the knowledge on the expression of phase I and phase II XMEs and transporters in extrahepatic tissues at the body's internal-external interfaces. In the lung, CYPs of families 1, 2, 3 and 4 and epoxide hydrolases are important phase I enzymes, while conjugation is less relevant. In skin, phase I-related enzymatic reactions are considered less relevant. Predominant skin XMEs are phase II enzymes, whereby glucuronosyltransferases (UGT) 1, glutathione- S-transferase (GST) and N-acetyltransferase (NAT) 1 are important for detoxification. The intestinal epithelium expresses many transporters and phase I XME with high levels of CYP3A4 and CYP3A5 and phase II metabolism is mainly related to UGT, NAT and Sulfotransferases (SULT). In the kidney, conjugation reactions and transporters play a major role for excretion processes. In the bladder, CYPs are relevant and among the phase II enzymes, NAT1 is involved in the activation of bladder carcinogens. Expression of XMEs is regulated by several mechanisms (nuclear receptors, epigenetic mechanisms, microRNAs). However, the understanding why XMEs are differently expressed in the various tissues is fragmentary. In contrast to the liver - where for most XMEs lower expression is demonstrated in early life - the XME ontogeny in the extrahepatic tissues remains to be investigated. [ABSTRACT FROM AUTHOR]

The gastrointestinal tract is a main route of exposure to polycyclic aromatic hydrocarbons (PAH) due to the ingestion of PAH-contaminated food. Numerous PAH are carcinogenic and most of them are metabolized to biologically active bay- and fjord-region dihydrodiol epoxides that are capable to form stable DNA adducts leading subsequently to mutations and cell transformation. In vitro studies with canine kidney epithelial cells demonstrate that detoxification of dihydrodiol epoxides through glutathione (GSH) conjugate formation catalyzed by glutathione S-transferases and their subsequent removal from the cell by transport proteins of the ATP-binding cassette superfamily is an important process to control DNA adduct levels. In the present study, Caco-2 cells were selected to serve as a model system to investigate both the human intestinal metabolism of the carcinogenic PAH benzo[a]pyrene (BP) and dibenzo[a,l]pyrene (DBP) and transport of their conjugates. In order to allow application of non labeled compounds specific LC-ESI-MS/MS methods were established to determine GSH conjugate formation of the dihydrodiol epoxides of BP and DBP and to demonstrate their efflux from Caco-2 cells. [ABSTRACT FROM PUBLISHER]